CD47 and neoplasm: The current paradigm regarding MOAs of CD47 targeting for cancer therapy is largely based on the tumor cell bearing CD47 targeting to block its binding to SIPRα ligand on macrophages and DCs13,14, which activate both anti-tumor innate and adaptive immunity.